Latest News
AstraZeneca reports positive Phase III results for Tagrisso and Orpathys
17 August 2026 - Biopharmaceutical company AstraZeneca (LSE: AZN) (STO: AZN) (NYSE: AZN) on Monday announced positive high-level results from the SAFFRON Phase III trial, showing Tagrisso (osimertinib) plus Orpathys (savolitinib) delivered statistica...
Henlius and Sandoz expand biosimilars collaboration
17 August 2026 - Shanghai-based biopharmaceutical company Shanghai Henlius Biotech, Inc. (HKG: 2696) said on Monday it has agreed a strategic collaboration with generic biosimilars company Sandoz Group AG (SIX: SDZ; OTCQX: SDZNY) covering up to 10 pr...
OmniAb signs global ion channel collaboration with Eli Lilly
17 August 2026 - Research technology company OmniAb Inc (NASDAQ: OABI) disclosed on Monday that it has entered into a global collaboration and licence agreement with medicine firm Eli Lilly and Company for a new ion channel programme, leveraging Omni...
HUTCHMED reports positive Phase III results for ORPATHYS and TAGRISSO combination
17 August 2026 - Biopharmaceutical company HUTCHMED (China) Limited (Nasdaq: HCM) (AIM: HCM) (HKEX: 13) on Monday announced positive high-level results from the SAFFRON Phase III trial, showing that ORPATHYS plus TAGRISSO delivered statistically sign...
Lttl announces new telehealth site
17 August 2026 - US-based, direct-to-consumer telehealth brand Lttl reported on Friday that it has launched a new site that specialises in personalised GLP-1 weight management, longevity protocols, and microdosed therapy.Lttl said it allows patients ...